Holen Sie sich die Stockscreener-App
86.46
1.48%
1.26
Handel nachbörslich:
86.93
0.47
+0.54%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CVS?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$85.20
Offen:
$85.25
24-Stunden-Volumen:
10.43M
Relative Volume:
1.40
Marktkapitalisierung:
$110.58B
Einnahmen:
$407.94B
Nettoeinkommen (Verlust:
$2.90B
KGV:
37.97
EPS:
2.2771
Netto-Cashflow:
$7.39B
1W Leistung:
-3.00%
1M Leistung:
-11.08%
6M Leistung:
+17.65%
1J Leistung:
+11.63%
1-Tages-Spanne:
$85.25
$87.15
1-Wochen-Bereich:
$84.23
$90.02
52-Wochen-Spanne:
$69.51
$110.68
Cvs Health Corp Stock (CVS) Company Profile
Firmenname
Cvs Health Corp
Sektor
Branche
Telefon
(401) 765-1500
Adresse
ONE CVS DR., WOONSOCKET
Compare CVS vs UNH, ELV, CI, HUM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CVS
Cvs Health Corp
|
86.46 | 113.99B | 407.94B | 2.90B | 7.39B | 2.2771 |
UNH
Unitedhealth Group Inc
|
371.90 | 327.80B | 450.13B | 14.91B | 23.62B | 15.55 |
ELV
Elevance Health Inc
|
386.43 | 85.90B | 201.11B | 4.95B | 6.29B | 22.50 |
CI
Cigna Group
|
270.53 | 71.88B | 278.13B | 6.74B | 7.66B | 23.60 |
HUM
Humana Inc
|
388.36 | 47.78B | 137.20B | 1.15B | 1.27B | 9.3439 |
Cvs Health Corp Stock (CVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-12 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2025-10-14 | Eingeleitet | Goldman | Buy |
| 2025-08-18 | Hochstufung | UBS | Neutral → Buy |
| 2025-08-14 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2025-02-13 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-02-12 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2025-01-30 | Hochstufung | Edward Jones | Hold → Buy |
| 2024-12-03 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-11-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-10-10 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2024-10-04 | Hochstufung | TD Cowen | Hold → Buy |
| 2024-05-30 | Eingeleitet | Robert W. Baird | Neutral |
| 2024-05-07 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-05-02 | Herabstufung | UBS | Buy → Neutral |
| 2024-05-01 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2024-05-01 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-03-06 | Eingeleitet | Barclays | Equal Weight |
| 2024-02-26 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-22 | Eingeleitet | HSBC Securities | Buy |
| 2023-09-19 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-09-12 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-08-18 | Herabstufung | Edward Jones | Buy → Hold |
| 2023-05-26 | Eingeleitet | Piper Sandler | Overweight |
| 2023-04-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-01-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-11-23 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-06-17 | Eingeleitet | Loop Capital | Buy |
| 2022-05-27 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2022-03-29 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2022-02-11 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2021-12-14 | Eingeleitet | Goldman | Buy |
| 2021-12-01 | Eingeleitet | Seaport Research Partners | Buy |
| 2021-05-19 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-03-17 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-01-08 | Hochstufung | Jefferies | Hold → Buy |
| 2020-09-17 | Eingeleitet | Piper Sandler | Overweight |
| 2020-07-01 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-05-14 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-09-27 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2019-09-12 | Eingeleitet | Deutsche Bank | Buy |
| 2019-06-05 | Hochstufung | Standpoint Research | Hold → Buy |
| 2019-04-29 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-04-18 | Eingeleitet | Guggenheim | Buy |
| 2019-04-15 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2019-04-10 | Bestätigt | BofA/Merrill | Buy |
| 2019-03-13 | Eingeleitet | Bernstein | Outperform |
| 2019-02-20 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2019-01-17 | Eingeleitet | UBS | Buy |
| 2018-12-18 | Eingeleitet | Barclays | Overweight |
| 2018-11-29 | Fortgesetzt | Goldman | Neutral |
| 2018-11-28 | Eingeleitet | Evercore ISI | Outperform |
| 2018-10-26 | Fortgesetzt | Wolfe Research | Peer Perform |
| 2018-07-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-02-27 | Fortgesetzt | BofA/Merrill | Buy |
| 2018-02-13 | Bestätigt | Citigroup | Neutral |
Alle ansehen
Cvs Health Corp Aktie (CVS) Neueste Nachrichten
Cardinal Health rises on extended CVS distribution deal - Investing.com
One profession with endless impact: Celebrating pharmacists - CVS Health
McKesson Corporation Extends Pharmaceutical Distribution Agreement with CVS Health - marketscreener.com
McKesson (MCK) and Cardinal Health Extend CVS Health Distributio - GuruFocus
McKesson extends CVS deal; shares rise - Investing.com
Why Is Cardinal Health and McKesson Stock Trading Higher TodayCVS Health (NYSE:CVS), McKesson (NYSE:MC - Benzinga
Cardinal Health renews contract with CVS Health - marketscreener.com
CVS Health stock costs EUR 76.14 as revenue grew 7.30 percent - AD HOC NEWS
CVS Health Corporation (NYSE:CVS) Declares Quarterly Dividend of $0.67 - MarketBeat
Cantor Fitzgerald reiterates CVS Health stock rating on MA margins - Investing.com India
UnitedHealthcare, Aetna say 2027 Medicare Advantage plans to offer more limited provider networks - Yahoo Finance
Cardinal Health Enters into Binding Letter of Intent to Extend Pharmaceutical Distribution Agreements with CVS Health - Yahoo Finance
CVS Health stock pre-market at EUR 75.75: plus 0.12 percent - AD HOC NEWS
CVS Health declares quarterly dividend of $0.665 per share - Investing.com
Cvs Health Declares Quarterly Dividend, Payable on November 2, 2026 - marketscreener.com
CVS Health (CVS) Declares Quarterly Dividend of $0.665 Per Share - GuruFocus
CVS Health Keeps Quarterly Dividend at $0.665 cents Per Share; Payable Nov. 2 to Shareholders of Record on Oct. 22 - marketscreener.com
A 66.5-cent CVS Health dividend is due Nov. 2. - Stock Titan
Prior authorization, reimagined: How CVS Caremark improves access to treatment - CVS Health
DHR's Growth Backed by Strong Biotechnology Unit: Can It Maintain the Pace? - Zacks Investment Research
CVS Health stock trades at EUR 76.94 with plus 0.18 percent - AD HOC NEWS
Hunger Action Month: Supporting healthier communities through better access to nutritious food - CVS Health
MiraSOFT™ Launch at CVS Pharmacy, Expanding the MIRA Portfolio with a Stool Softener Option - Yahoo Finance
CVS Health: Value-Based Care Is Hard, but It's Worth Getting Right - FinanzNachrichten.de
CVS Health Corp. stock underperforms Monday when compared to competitors - MarketWatch
Ask a CVS Pharmacist: Your top flu shot questions, answered - CVS Health
CVS Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of CVS Health CorporationCVS - Business Wire
CVS Health Is Making a Difference in Local Communities, One Classroom at a Time - Yahoo Finance
CVS Health stock at USD 89.13 on September 25, 2026 - AD HOC NEWS
CVS Health Corp (CVS) Shares Surge 4.8% -- What GF Score of 81 T - GuruFocus
CVS Health Corp. stock outperforms competitors on strong trading day - MarketWatch
Why is CVS Health stock rallying today? - Investing.com
Why is CVS Health stock rallying today? By Investing.com - Investing.com Canada
CVS rises as investors revisit stronger guidance and fading Omnicare overhang - Quiver Quantitative
CVS Health Corp Stock (CVS) Moved Up by 3.65% on Sep 25: What Signal Does It Send? - TradingKey
CVS Health stock trades at USD 85.21 as Q2 revenue rises 7.3 percent - AD HOC NEWS
CVS Health Strengthens Energy Resilience To Support Patient Care - ACCESS Newswire
CVS Health stock heads into the open after an 1.2 percent drop - ad-hoc-news.de
CVS Looks 7.6% Overvalued on GF Value™ as Dividend Sustainabilit - GuruFocus
What Should CVS Stock Investors Be Watching Now? - Yahoo Finance
After 30 years, a Hepatitis C treatment that finally worked - CVS Health
Aetna expands cancer treatment prior authorization bundles - Investing.com
CVS Health; Criteo Agree to Pay Combined $20.5 Million to Resolve Website Tracking Litigation - The HIPAA Journal
Aetna Expands Bundled Oncology Prior Authorizations, Easing Provider Burden and Accelerating Member Access to Care - finance.yahoo.com
CVS Health Corporation (CVS) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
CVS online shoppers could get cash from $20.5M settlement - The Clarion-Ledger
QRG Capital Management Inc. Raises Stock Holdings in CVS Health Corporation $CVS - MarketBeat
Envestnet Asset Management Inc. Boosts Stake in CVS Health Corporation $CVS - MarketBeat
CVS Health stock slips 1.4 percent ahead of the open - AD HOC NEWS
CVS Health stock falls 2.93 percent at the close - AD HOC NEWS
CVS Health Corp. stock outperforms competitors despite losses on the day - MarketWatch
Finanzdaten der Cvs Health Corp-Aktie (CVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cvs Health Corp-Aktie (CVS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| ROBBINS LARRY | Director |
May 19 '26 |
Sale |
94.45 |
1,983,538 |
187,341,308 |
6,213,261 |
| ROBBINS LARRY | Director |
May 20 '26 |
Sale |
93.82 |
1,018,000 |
95,510,822 |
5,195,261 |
| ROBBINS LARRY | Director |
May 21 '26 |
Sale |
93.45 |
370,462 |
34,619,007 |
4,824,799 |
1.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):